Tasmar Side Effects May Lead To Stroke Lawsuits
Tasmar | Lawsuits, Lawyers | Side Effects: Stroke, Pulmonary Embolism, Blood Clots, Uterus Cancer
Tasmar, also known as tolcapone, is a C.O.M.T. inhibitor and is used to treat symptoms associated with Parkinson's disease. Tasmar is often used in combination with other Parkinson medications such as levodopa and carbidopa. First approved in January 1998, about ten months on the market Tasmar warnings were issued and a boxed warning was added to Tasmar product labeling. Physicians prescribing Tasmar was advised about reports of a new finding of fatal liver injury associated with the use of Tasmar.
In 1998 Roche issued a warning letter to doctors informing them of the increased risk of liver problems in patients taking Tasmar. The letter suggests that doctors only give Tasmar to those patients who do not respond to other similar medications.
The drug has caused fatal liver failure in at least three people. The more than 60,000 people who have taken Tasmar may be 100 times more likely to develop liver problems than those who have not taken the drug. Roche refers to the liver damage caused by Tasmar as a "hepatocellular injury.
The adverse Tasmar effects led the manufacturer and the FDA to recommend significant changes in how Tasmar is used, reserved only for patients who do not have severe movement abnormalities and who do not respond to or who are not appropriate candidates for alternate treatments. Patients were advised to self-monitor themselves while on Tasmar for signs of liver disease, including jaundice, fatigue, and loss of appetite. In addition, patients that fail to show a substantial clinical benefit in the initial three weeks of Tasmar treatment were advised to be withdrawn from the drug.
Legal Help For Victims Affected By Tasmar
If you or a loved one were affected by Tasmar, please fill out the form at the right for a free case evaluation by a qualified attorney or call us anytime at 1-800-YOURLAWYER (1-800-968-7529).